Exhibit 99.1

Contact:		Jake Elguicze Vice President Investor Relations 610-948-2836

FOR IMMEDIATE RELEASE		July 22, 2010

TELEFLEX REPORTS SECOND QUARTER 2010 RESULTS

Second Quarter revenues up 5% as reported; core revenue up 7%

Second Quarter diluted adjusted EPS from Continuing Operations of $1.04 per share, up 4%

Second Quarter diluted GAAP EPS from Continuing Operations of $1.04 per share, up 27%

CFG Approval Received from FDA

Limerick, PA — Teleflex Incorporated (NYSE: TFX) today announced financial results for the second quarter and year to date ended June 27, 2010.

Financial Highlights

Second quarter 2010 net revenues increased 5% to $461.7 million from $439.2 million in the second quarter of 2009. Core revenues for the quarter increased 7%, offset by foreign currency translation which negatively impacted sales 1%, and the deconsolidation of an entity which negatively impacted sales 1%.

Second quarter 2010 GAAP income from continuing operations attributable to common shareholders increased 28% to $42.0 million, or $1.04 per diluted share, compared to $32.8 million, or $0.82 per diluted share in the prior year quarter. On an adjusted basis, as detailed in the reconciliation tables below, second quarter 2010 income from continuing operations increased 5% to $41.9 million, or $1.04 per diluted share, compared to $39.9 million, or $1.00 per diluted share, in the prior year quarter.

Second quarter 2010 GAAP net income attributable to common shareholders was $60.1 million compared to $6.5 million in the prior year quarter. These results included income from discontinued operations of $18.1 million in the second quarter of 2010, and a loss from discontinued operations of $26.4 million in the prior year quarter.

Net revenues for the first six months of 2010 increased 3% to $882.9 million from $854.3 million in 2009. Core revenues increased 3%, foreign currency translation increased sales 1%, while the disposition of a product line and the deconsolidation of an entity, together, accounted for a 1% decline in revenues.

GAAP income from continuing operations attributable to common shareholders for the first six months of 2010 increased 37% to $76.9 million, or $1.91 per diluted share, compared to $56.0 million, or $1.40 per diluted share, in the first six months of 2009. On an adjusted basis, as detailed in the reconciliation tables below, income from continuing operations for the first six months of 2010 increased 16% to $77.2 million, or $1.92 per diluted share, compared to $66.8 million, or $1.67 per diluted share, in the first six months of 2009.

GAAP net income attributable to common shareholders for the first six months of 2010 was $97.8 million compared to $222.0 million in the first six months of 2009. These results included income from discontinued operations of $20.9 million in the first six months of 2010, and income from discontinued operations of $166.0 million in the first six months of 2009.

GAAP cash flow from continuing operations for the first six months of 2010 was $100.2 million as compared to cash used in continuing operations of $27.8 million in the first six months of 2009. On an adjusted basis as detailed in the reconciliation tables below, cash flow from continuing operations for the first six months of 2010 was $80.4 million as compared to $69.8 million in 2009.

In the third quarter of 2010, the Company began submitting requests for certificates to foreign governments, or CFGs, to the FDA for review, and recently received approval on one of its requests. The Company believes that the FDA’s approval of the CFG is a clear indication that it has substantially corrected the quality system issues identified in the corporate warning letter. The Company has now submitted all of its currently eligible CFG requests to the FDA for review and currently anticipates receiving the FDA’s approval with respect to most of these requests in the third quarter of 2010.

The Company also announced organizational and leadership changes associated with its continued transition to a medical technology business. The new structure and leadership are designed to support strategic and financial objectives for the growth of the medical business globally.

The Company has consolidated its Corporate and Medical executive management teams to create a single Teleflex Leadership Team reporting directly to Jeff Black, Chairman and Chief Executive Officer. Teleflex also announced that the position of President, Teleflex Medical has been eliminated and Ernest Waaser will be leaving the Company. Mr. Waaser, who held this position for four years, will remain with the company through a transition period.

“In planning for this transition, Ernest and I recognized some time ago that the position of President, Teleflex Medical would likely be eliminated,” stated Black. “Ernest and I have worked closely together over the last four years to execute integration plans, complete FDA audits related to the corporate warning letter, and enhance our quality systems and information systems infrastructure. I very much want to thank him for his efforts and wish him well in his new endeavors.”

Added Black, “I am extremely pleased by the recent approval by the FDA of one of our CFG requests. Over the past few years there has been a tremendous amount of work put into FDA remediation efforts, and although we do not expect this CFG approval to have a material impact on revenues for the remainder of 2010, this is clearly a positive sign for our future. Looking ahead, we have set clear long term strategic and financial goals for Teleflex and we believe that we have significant opportunity to stimulate sales growth, leverage our global sales channels, expand in emerging markets, and create innovative new products that serve our customers and their patients.”

Second Quarter Business Segment Commentary

Medical Segment

Medical Segment revenues in the second quarter of 2010 were $358.4 million as compared to $358.3 million in the prior year period. Core revenue growth of 2% was offset by an unfavorable currency impact of 1%, and impact of the deconsolidation of an entity of 1%. Core revenue increases in respiratory, urology, anesthesia, cardiac care and specialty products sold to medical OEM’s were offset by a decline in surgical and vascular access sales. The decline in vascular access sales was due to the voluntary recall of custom IV tubing product that was announced in February of 2010.

Medical Segment sales by product group were comprised of the following:

		Three Months Ended								% Increase/ (Decrease)
										Core				Currency/				Total
		June 27, 2010				June 28, 2009				Growth				Other*				Change
		(Dollars in millions)
Critical Care		$	233.7			$	230.9				2	%			(1	%)			1	%
Surgical			66.2				67.5				(1	%)			(1	%)			(2	%)
Cardiac Care			18.8				19.3				1	%			(4	%)			(3	%)
OEM			39.0				37.7				4	%			(1	%)			3	%
Other*			0.7				2.9				75	%			(152	%)			(77	%)
Total net sales		$	358.4			$	358.3				2	%			(2	%)			—

Segment operating profit and margins in the second quarter of 2010 were $73.5 million, or 20.5%, compared to $77.8 million, or 21.7%, in the prior year quarter. Excluding the $0.5 million impact of integration costs not qualified for restructuring, segment operating profit and margins in the second quarter of 2009 were $78.3 million, or 21.8%, as noted in the reconciliation tables below.

Aerospace Segment

Aerospace Segment revenues in the second quarter of 2010 increased 30% to $48.0 million from $37.0 million in the prior year period. Increases in sales of wide-body cargo handling systems to OEM’s, actuation product, and cargo containers and cargo spares and repair sales, more than offset lower sales of narrow-body cargo handling systems, resulting in a 32% increase in core revenue during the quarter. This was somewhat offset by an unfavorable currency impact of 2%.

Segment operating profit and margins in the second quarter of 2010 were $7.6 million, or 15.8%, compared to $1.0 million, or 2.8%, in the prior year quarter.

Commercial Segment

Commercial Segment revenues in the second quarter of 2010 increased 26% to $55.3 million from $44.0 million in the same period last year. Core revenue growth of 25% was the result of increased sales of Marine OEM and aftermarket sales. Foreign currency was favorable by 1%.

Segment operating profit and margins in the second quarter of 2010 were $7.5 million, or 13.6%, compared to $3.3 million, or 7.5%, in the prior year quarter.

Balance Sheet Highlights

Cash and cash equivalents on hand at June 27, 1010 was $287.1 million compared to $188.3 million at December 31, 2009, up 52%.

Net accounts receivable at June 27, 1010 were $291.4 million compared to $265.3 million at December 31, 2009, up 10%. Excluding the $39.7 million impact of the adoption of the amendment to Accounting Standards Codification topic 860 “Transfers and Servicing” (“ASC 860”), net accounts receivable declined 5%.

Net inventory at June 27, 1010 was $337.4 million compared to $360.8 million at December 31, 2009, a decline of 6%.

Net debt at June 27, 1010 was $882.5 million compared to $1,008.2 million at December 31, 2009, a decline of 12%. Excluding the $39.7 million impact of ASC 860, net debt declined 16%.

Business Outlook for 2010

The Company’s financial estimates for 2010 include total revenues of approximately $1.8 billion and diluted earnings per share from continuing operations excluding special items in the range of $3.95 to $4.10. Cash flow from continuing operations, exclusive of the impact of the adoption of ASC 860, is expected to be in the range of $265 to $270 million. Restructuring and other special charges related to the Arrow integration program are anticipated to be $0.05 per diluted share for the year.

Conference Call Webcast and Additional Information

As previously announced, Teleflex will comment on its second quarter results on a conference call to be held today at 4:30 p.m. (ET). The call will be available live and archived on the Company’s website at www.teleflex.com and the accompanying presentation will be posted prior to the call. An audio replay will be available until July 29, 2010, 12:00pm (ET), by calling 888-286-8010 (U.S./Canada) or 617-801-6888 (International), Passcode: 80213544.

Additional Notes

Core revenue and growth include activity of a purchased company beyond the initial twelve months after the date of acquisition. Core growth excludes the impact of translating the results of international subsidiaries at different currency exchange rates from period to period, and the activity of companies that have been divested within the most recent twelve month period.

Certain financial information is presented on a rounded basis, which may cause minor differences.

Segment operating profit includes a segment’s net revenues reduced by its materials, labor and other product costs along with the segment’s selling, engineering and administrative expenses and non-controlling interest. Unallocated corporate expenses, gains or losses on sales of assets, restructuring and impairment charges, interest income and expense and taxes on income are excluded from the measure.

Segment commentary excludes the impact of discontinued operations, items included in restructuring and impairment charges, and losses and other charges as disclosed in the condensed consolidated statements of income.

Notes on Non-GAAP Financial Measures

This press release includes financial measures which exclude the effect of charges associated with our restructuring programs and asset impairments, charges related to the Arrow acquisition, (gain)/loss on sale of assets and other charges, the impact of changes in accounting rules, an income tax refund related to gains on a business divestiture, and intangible amortization expense. Adjusted cash earnings per share from continuing operations is defined as adjusted earnings per share from continuing operations plus intangible amortization expense. Management believes these measures are useful to investors because they eliminate items that do not reflect Teleflex’s day-to-day operations. In addition, management uses these financial measures for internal managerial purposes, when publicly providing guidance on possible future results, and to assist in our evaluation of period-to-period comparisons. These financial measures are presented in addition to results presented in accordance with GAAP and should not be relied upon as a substitute for GAAP financial measures. Tables reconciling these non-GAAP measures to the most directly comparable GAAP measures are set forth below.

Second Quarter and Year to Date Reconciliation of Adjusted Income and Earnings per Share from Continuing Operations

		Three Months				Three Months
		Ended				Ended
		June 27, 2010				June 28, 2009
		(Dollars in thousands, except per share)
Income and diluted earnings per share attributable to common shareholders		$	42,003			$	32,834
		$	1.04			$	0.82
Restructuring and impairment charges			75				12,894
Tax benefit			(157	)			(1,844	)
Restructuring and impairment charges, net of tax			(82	)			11,050
		$	0.00			$	0.28
Losses and other charges (A)			—				480
Tax benefit			—				(164	)
Losses and other charges net of tax			—				316
						$	0.01
Tax adjustments (B)			—				(4,305	)
			—			$	(0.11	)
Income and diluted earnings per share excluding restructuring and impairment charges, losses and other charges, and tax adjustments		$	41,921			$	39,895
		$	1.04			$	1.00

		Three Months				Three Months
		Ended				Ended
		June 27, 2010				June 28, 2009
		(Dollars in thousands, except per share)
Income and diluted earnings per share excluding restructuring and impairment charges, losses and other charges, and tax adjustments		$	41,921			$	39,895
		$	1.04			$	1.00
Intangible amortization expense			11,293				10,742
		$	0.28			$	0.27
Cash income and diluted earnings per share excluding restructuring and impairment charges, losses and other charges, and tax adjustments		$	53,214			$	50,637
		$	1.32			$	1.27

		Six Months				Six Months
		Ended				Ended
		June 27, 2010				June 28, 2009
		(Dollars in thousands, except per share)
Income and diluted earnings per share attributable to common shareholders		$	76,936			$	56,003
		$	1.91			$	1.40
Restructuring and impairment charges			538				15,357
Tax benefit			(272	)			(2,560	)
Restructuring and impairment charges, net of tax			266				12,797
		$	0.01			$	0.32
Losses and other charges (A)			—				3,706
Tax benefit			—				(1,375	)
Losses and other charges net of tax			—				2,331
						$	0.06
Tax adjustments (B)			—				(4,305	)
			—			$	(0.11	)
Income and diluted earnings per share excluding restructuring and impairment charges, losses and other charges, and tax adjustments		$	77,202			$	66,826
		$	1.92			$	1.67

		Six Months				Six Months
		Ended				Ended
		June 27, 2010				June 28, 2009
		(Dollars in thousands, except per share)
Income and diluted earnings per share excluding restructuring and impairment charges, losses and other charges, and tax adjustments		$	77,202			$	66,826
		$	1.92			$	1.67
Intangible amortization expense			22,261				21,525
		$	0.55			$	0.54
Cash income and diluted earnings per share excluding restructuring and impairment charges, losses and other charges, and tax adjustments		$	99,463			$	88,351
		$	2.47			$	2.21

Second Quarter and Year to Date Reconciliation of Adjusted Medical Segment Operating Profit and Margin

		Three Months Ended				Three Months Ended
		June 27, 2010				June 28, 2009
		(Dollars in thousands)
Medical Segment operating profit as reported		$	73,467			$	77,792
Medical Segment operating margin as reported			20.5	%			21.7	%
Add: Integration costs not qualified for restructuring			—				480
Adjusted Medical Segment operating profit		$	73,467			$	78,272
Adjusted Medical Segment operation margin			20.5	%			21.8	%

		Six Months Ended				Six Months Ended
		June 27, 2010				June 28, 2009
		(Dollars in thousands)
Medical Segment operating profit as reported		$	146,965			$	147,204
Medical Segment operating margin as reported			20.9	%			21.2	%
Add: Integration costs not qualified for restructuring			—				1,109
Adjusted Medical Segment operating profit		$	146,965			$	148,313
Adjusted Medical Segment operation margin			20.9	%			21.4	%

Year to Date Reconciliation of Cash Flow from Operations

		Six Months Ended				Six Months Ended
		June 27, 2010				June 28, 2009
		(Dollars in thousands)
Cash flow from operations as reported		$	100,154			$	(27,755	)
Add: Impact of the adoption of the amendment to Accounting Standards Codification topic 860 “Transfers and Servicing”			39,700				—
Add: Tax payments on gain on sale of ATI business			—				97,536
Less: Tax refund on sale of ATI business			59,499				—
Adjusted cash flow from operations		$	80,355			$	69,781

Net Debt Reconciliation

		June 27, 2010				December 31, 2009
		(Dollars in thousands)
Note payable and current portion of long-term borrowings		$	41,464			$	4,008
Long term borrowings			1,128,200				1,192,491
Total debt			1,169,664				1,196,499
Less: cash and cash equivalents			287,129				188,305
Net Debt		$	882,535			$	1,008,194

About Teleflex Incorporated

Teleflex is a global provider of medical technology products that enable healthcare providers to improve patient outcomes, reduce infections and support patient and provider safety. Teleflex, which employs approximately 12,600 people worldwide, also has niche businesses that serve segments of the aerospace and commercial markets with specialty engineered products. Additional information about Teleflex can be obtained from the Company’s website at www.teleflex.com.

Caution Concerning Forward-looking Information

This press release contains forward-looking statements, including, but not limited to, statements relating to our 2010 forecast of total revenues; forecasted diluted earnings per share from continuing operations excluding special items; forecasted cash flow from continuing operations, excluding the impact of Accounting Standards Codification Topic 860 “Transfers and Servicing;” expected restructuring and other special charges related to the Arrow restructuring for 2010. Actual results could differ materially from those in the forward-looking statements due to, among other things, conditions in the end markets we serve, customer reaction to new products and programs, our ability to achieve sales growth, price increases or cost reductions; changes in the reimbursement practices of third party payors; our ability to realize efficiencies and to execute on our strategic initiatives; changes in material costs and surcharges; market acceptance and unanticipated difficulties in connection with the introduction of new products and product line extensions; unanticipated difficulties in connection with the consolidation of manufacturing and administrative functions; unanticipated difficulties, expenditures and delays in complying with government regulations applicable to our businesses, including unanticipated costs and difficulties in connection with the resolution of issues related to the FDA corporate warning letter issued to Arrow; the impact of government healthcare reform legislation; our ability to meet our debt obligations; changes in general and international economic conditions; and other factors described in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

TELEFLEX INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)

		Three Months Ended
		June 27,				June 28,
		2010				2009
		(Dollars and shares in thousands,
		except per share)
Net revenues		$	461,675			$	439,237
Cost of goods sold			252,874				241,185
Gross profit			208,801				198,052
Selling, general and administrative expenses			118,506				117,614
Research and development expenses			10,867				8,420
Goodwill impairment			—				6,728
Restructuring and other impairment charges			75				6,166
Income from continuing operations before interest and taxes			79,353				59,124
Interest expense			19,585				21,999
Interest income			(176	)			(1,459	)
Income from continuing operations before taxes			59,944				38,584
Taxes on income from continuing operations			17,563				5,448
Income from continuing operations			42,381				33,136
Operating income (loss) from discontinued operations (including gain on disposal of $28,825 in 2010)			30,476				(25,104	)
Taxes on income from discontinued operations			12,331				1,260
Income (loss) from discontinued operations			18,145				(26,364	)
Net income			60,526				6,772
Less: Net income attributable to noncontrolling interest			378				302
Net income attributable to common shareholders		$	60,148			$	6,470
Earnings per share available to common shareholders:
Basic:
Income from continuing operations		$	1.05			$	0.83
Income (loss) from discontinued operations		$	0.45			$	(0.66	)
Net income		$	1.51			$	0.16
Diluted:
Income from continuing operations		$	1.04			$	0.82
Income (loss) from discontinued operations		$	0.45			$	(0.66	)
Net income		$	1.49			$	0.16
Dividends per share		$	0.34			$	0.34
Weighted average common shares outstanding:
Basic			39,913				39,717
Diluted			40,356				39,921
Amounts attributable to common shareholders:
Income from continuing operations, net of tax		$	42,003			$	32,834
Income (loss) from discontinued operations, net of tax			18,145				(26,364	)
Net income		$	60,148			$	6,470

TELEFLEX INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)

		Six Months Ended
		June 27,				June 28,
		2010				2009
		(Dollars and shares in thousands,
		except per share)
Net revenues		$	882,874			$	854,280
Cost of goods sold			479,724				471,897
Gross profit			403,150				382,383
Selling, general and administrative expenses			233,794				232,535
Research and development expenses			20,427				15,985
Net loss on sales of businesses and assets			—				2,597
Goodwill impairment			—				6,728
Restructuring and other impairment charges			538				8,629
Income from continuing operations before interest and taxes			148,391				115,909
Interest expense			38,619				47,396
Interest income			(394	)			(1,668	)
Income from continuing operations before taxes			110,166				70,181
Taxes on income from continuing operations			32,566				13,640
Income from continuing operations			77,600				56,541
Operating income from discontinued operations (including gain on disposal of $38,562 in 2010 and $275,787 in 2009)			41,301				278,386
Taxes on income from discontinued operations			20,417				102,548
Income from discontinued operations			20,884				175,838
Net income			98,484				232,379
Less: Net income attributable to noncontrolling interest			664				538
Income from discontinued operations attributable to noncontrolling interest			—				9,860
Net income attributable to common shareholders		$	97,820			$	221,981
Earnings per share available to common shareholders:
Basic:
Income from continuing operations		$	1.93			$	1.41
Income from discontinued operations		$	0.52			$	4.18
Net income		$	2.45			$	5.59
Diluted:
Income from continuing operations		$	1.91			$	1.40
Income from discontinued operations		$	0.52			$	4.16
Net income		$	2.43			$	5.56
Dividends per share		$	0.68			$	0.68
Weighted average common shares outstanding:
Basic			39,852				39,704
Diluted			40,277				39,899
Amounts attributable to common shareholders:
Income from continuing operations, net of tax		$	76,936			$	56,003
Income from discontinued operations, net of tax			20,884				165,978
Net income		$	97,820			$	221,981

TELEFLEX INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)

		June 27,				December 31,
		2010				2009
		(Dollars in thousands)
ASSETS
Current assets
Cash and cash equivalents		$	287,129			$	188,305
Accounts receivable, net			291,386				265,305
Inventories, net			337,363				360,843
Prepaid expenses and other current assets			21,277				21,872
Income taxes receivable			34,418				100,733
Deferred tax assets			55,774				58,010
Assets held for sale			8,037				8,866
Total current assets			1,035,384				1,003,934
Property, plant and equipment, net			290,761				317,499
Goodwill			1,409,197				1,459,441
Intangibles assets, net			925,992				971,576
Investments in affiliates			14,007				12,089
Deferred tax assets			—				336
Other assets			68,403				74,130
Total assets		$	3,743,744			$	3,839,005
LIABILITIES AND EQUITY
Current liabilities
Current borrowings		$	41,464			$	4,008
Accounts payable			82,119				94,983
Accrued expenses			76,414				97,274
Payroll and benefit-related liabilities			66,732				70,537
Derivative liabilities			15,108				16,709
Accrued interest			21,330				22,901
Income taxes payable			11,216				30,695
Deferred tax liabilities			6,926				—
Total current liabilities			321,309				337,107
Long-term borrowings			1,128,200				1,192,491
Deferred tax liabilities			400,334				398,923
Pension and postretirement benefit liabilities			162,788				164,726
Other liabilities			149,371				160,684
Total liabilities			2,162,002				2,253,931
Commitments and contingencies
Total common shareholders’ equity			1,577,232				1,580,241
Noncontrolling interest			4,510				4,833
Total equity			1,581,742				1,585,074
Total liabilities and equity		$	3,743,744			$	3,839,005

TELEFLEX INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

		Six Months Ended
		June 27, 2010				June 28, 2009
		(Dollars in thousands)
Cash Flows from Operating Activities of Continuing Operations:
Net income		$	98,484			$	232,379
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Income from discontinued operations			(20,884	)			(175,838	)
Depreciation expense			24,444				27,573
Amortization expense of intangible assets			22,261				21,525
Amortization expense of deferred financing costs			1,890				3,610
Impairment of long-lived assets			—				2,474
Impairment of goodwill			—				6,728
Stock-based compensation			4,901				4,000
Net loss on sales of businesses and assets			—				2,597
Deferred income taxes, net			23,120				27,141
Other			427				2,932
Changes in operating assets and liabilities, net of effects of acquisitions and disposals:
Accounts receivable			(56,797	)			568
Inventories			(4,392	)			(11,228	)
Prepaid expenses and other current assets			921				1,341
Accounts payable and accrued expenses			(20,169	)			(31,260	)
Income taxes receivable and payable, net			25,948				(142,297	)
Net cash provided by (used in) operating activities from continuing operations			100,154				(27,755	)
Cash Flows from Investing Activities of Continuing Operations:
Expenditures for property, plant and equipment			(15,315	)			(14,197	)
Proceeds from sales of businesses and assets, net of cash sold			74,734				300,000
Payments for businesses and intangibles acquired, net of cash acquired			(81	)			(541	)
Net cash provided by investing activities from continuing operations			59,338				285,262
Cash Flows from Financing Activities of Continuing Operations:
Proceeds from long-term borrowings			—				10,000
Reduction in long-term borrowings			(64,170	)			(249,178	)
Increase (decrease) in notes payable and current borrowings			39,700				(651	)
Proceeds from stock compensation plans			8,032				367
Payments to noncontrolling interest shareholders			(637	)			(295	)
Dividends			(27,120	)			(27,014	)
Net cash used in financing activities from continuing operations			(44,195	)			(266,771	)
Cash Flows from Discontinued Operations:
Net cash (used in) provided by operating activities			(680	)			26,126
Net cash used in investing activities			(189	)			(1,984	)
Net cash used in financing activities			—				(11,075	)
Net cash (used in) provided by discontinued operations			(869	)			13,067
Effect of exchange rate changes on cash and cash equivalents			(15,604	)			3,192
Net increase in cash and cash equivalents			98,824				6,995
Cash and cash equivalents at the beginning of the period			188,305				107,275
Cash and cash equivalents at the end of the period		$	287,129			$	114,270

Information about continuing operations by business segment is as follows:

		Three Months Ended
		June 27,				June 28,
		2010				2009
		(Dollars in thousands)
Segment data:
Medical		$	358,427			$	358,278
Aerospace			47,995				36,961
Commercial			55,253				43,998
Segment net revenues		$	461,675			$	439,237
Medical		$	73,467			$	77,792
Aerospace			7,561				1,020
Commercial			7,487				3,286
Segment operating profit			88,515				82,098
Less: Corporate expenses			9,465				10,382
Goodwill impairment			—				6,728
Restructuring and impairment charges			75				6,166
Noncontrolling interest			(378	)			(302	)
Income from continuing operations before interest and taxes		$	79,353			$	59,124

		Six Months Ended
		June 27,				June 28,
		2010				2009
		(Dollars in thousands)
Segment data:
Medical		$	701,964			$	693,063
Aerospace			84,868				80,690
Commercial			96,042				80,527
Segment net revenues		$	882,874			$	854,280
Medical		$	146,965			$	147,204
Aerospace			9,305				4,057
Commercial			9,461				3,636
Segment operating profit			165,731				154,897
Less: Corporate expenses			17,466				21,572
Net loss on sales of businesses and assets			—				2,597
Goodwill impairment			—				6,728
Restructuring and impairment charges			538				8,629
Noncontrolling interest			(664	)			(538	)
Income from continuing operations before interest and taxes		$	148,391			$	115,909

###